2015-01-13T16:47:20-06:00 2014-06-30 135381590 BDO USA LLP 7101 WISCONSIN AVE SUITE 800 BETHESDA MD 208144827 990 2013-07-01 263690883 THE LIEBER INSTITUTE INC LIEB 4109551000 855 N WOLFE STREET 3RD FLOOR BALTIMORE MD 21205 ANDREW MASLAN CFO 4109551000 2015-01-13 1 MICHAEL SORRELLS CPA P00001737 3016544900 2013 2016-02-25 16:41:14Z DANIEL WEINBERGER 855 N WOLFE STREET 3RD FLOOR BALTIMORE MD 21205 18529724 0 X LIBD.ORG X 2008 MD THE MISSION OF THE LIEBER INSTITUTE FOR BRAIN DEVELOPMENT IS THE STUDY OF SCHIZOPHRENIA AND RELATED DISORDERS, IN ORDER TO SPUR THE IDENTIFICATION AND TESTING OF NEW MEDICATIONS TO TREAT SUCH DISORDERS. 9 8 106 0 0 0 150000 441315 527526 5000506 1104915 2677850 1084156 915142 2866597 9034813 450000 427500 0 0 7715150 10081399 65000 50000 50000 7569813 10101565 15799963 20660464 -12933366 -11625651 100309339 91491249 5641028 7042291 94668311 84448958 X THE MISSION OF THE LIEBER INSTITUTE FOR BRAIN DEVELOPMENT IS THE STUDY OF SCHIZOPHRENIA AND RELATED DISORDERS, IN ORDER TO SPUR THE IDENTIFICATION AND TESTING OF NEW MEDICATIONS TO TREAT SUCH DISORDERS. 1 0 5724810 915234 BASIC SCIENCES: THE CREATION OF MODEL SYSTEMS AT THE LIEBER INSTITUTE TO STUDY PSYCHIATRIC ILLNESS IS THE MAJOR GOAL OF THE BASIC SCIENCES RESEARCH PROGRAM. USING OUR UNIQUE COLLECTION OF HUMAN BRAIN MATERIAL AND INDUCED PLURIPOTENT STEM CELL LINES, WE ARE DEFINING THE MOLECULAR SIGNATURE OF DISEASE RISK. TO PROVIDE THE BASIS FOR THERAPEUTIC INTERVENTION WE ARE DEVELOPING NEW TECHNOLOGIES USING HUMAN STEM CELLS TO IDENTIFY THE FUNCTIONAL CONSEQUENCES OF GENETIC RISK FACTORS. WITHIN THE BASIC SCIENCES DIVISION, THE LIEBER INSTITUTE HAS PROGRAMS IN STEM CELL GENETICS, IMAGING DEVELOPMENT, CIRCUIT ACTIVATION, NEUROPLASTICITY, AND ELECTROPHYSIOLOGY. 8723211 2195600 CLINICAL SCIENCES: THE CLINICAL SCIENCE DIVISION INVESTIGATES MECHANISMS OF SCHIZOPHRENIA AND RELATED BRAIN DISORDERS IN CLINICAL STUDIES AND IN BIOLOGICAL MATERIAL FROM CLINICAL SAMPLES SPECIFICALLY ASCERTAINED, EVALUATED AND MANAGED BY LIEBER INSTITUTE STAFF AND BY LIEBER INSTITUTE STAFF OVERSIGHT OF COLLABORATIONS WITH THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH), PEKING UNIVERSITY, UNIVERSITY OF BARI (ITALY), AND OTHERS. WITHIN THE CLINICAL SCIENCES DIVISION, THE LIEBER INSTITUTE HAS PROGRAMS IN: GENETICS, EPIGENETICS AND BIOINFORMATICS; COGNITIVE NEUROSCIENCE AND IMAGING GENETICS; NEUROPATHOLOGY, AND CLINICAL PHARMACOLOGY AND PHARMACOGENETICS. 2376810 1889672 DRUG DISCOVERY: IMPROVED GENETIC UNDERSTANDING OF DISEASES OF BRAIN DEVELOPMENT IS REVEALING NEW DRUG DISCOVERY OPPORTUNITIES. GUIDED BY GENETICS, THE LIEBER INSTITUTE DRUG DISCOVERY DIVISION IS INVESTIGATING NEW TARGETS FOR PSYCHIATRIC DISEASES, WITH THE GOAL OF VALIDATING INNOVATIVE APPROACHES THAT WILL LEAD TO NOVEL MEDICINES FOR PATIENTS SUFFERING FROM PSYCHIATRIC DISEASE. THE DRUG DISCOVERY DIVISION MAINTAINS A STATE OF THE ART MEDICINAL CHEMISTRY LABORATORY AND UNIQUE CAPABILITIES IN TARGET VALIDATION. 427500 427500 EXTRAMURAL GRANTS: THE INSTITUTE WILL OFFER GRANTS FOR RESEARCH PROJECTS DONE VIA FORMAL COLLABORATIVE AGREEMENTS WITH EXTERNAL SCIENTISTS AND/OR ORGANIZATIONS. RESEARCH PROJECTS WILL SUPPORT THE INSTITUTE'S GOAL OF DEVELOPING NEW CLASSES OF TREATMENTS, DIAGNOSTIC TESTS AND NEW INSIGHTS INTO THE ETIOLOGY OF BEHAVIORAL DISORDERS STEMMING FROM ABNORMALITIES IN HUMAN BRAIN DEVELOPMENT. EXTERNAL RESEARCH PROJECTS WILL ALIGN WITH THE INSTITUTE'S PORTFOLIO OF ACTIVITIES IN DISCIPLINES SUCH AS STEM CELL BIOLOGY, DEVELOPMENT NEUROBIOLOGY, FUNCTIONAL GENOMICS, CLINICAL GENETICS, COGNITIVE NEUROSCIENCE, BIOINFORMATICS, AND IMAGING. THE GOAL OF THIS PROGRAM IS TO BENEFIT FROM RESEARCH AND TECHNICAL EXPERTISE WORLDWIDE IN ORDER TO EXPAND THE OPPORTUNITIES FOR THE INSTITUTE TO FIND TREATMENTS OR A CURE FOR SCHIZOPHRENIA. 427500 427500 17252331 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 47 0 1 106 1 0 0 0 0 0 0 0 0 0 0 X 9 8 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 X NORMAN WEISMAN 4432877065 855 N WOLFE STREET SUITE 300 BALTIMORE MD 21205 X HERBERT PARDES MD CHAIRMAN OF THE BOARD 1.00 X 0 0 0 RONALD J DANIELS DIRECTOR 1.00 X 0 0 0 STEVE LIEBER DIRECTOR 1.00 X 0 0 0 CONSTANCE LIEBER PRESIDENT/SECRETARY 1.00 X 0 0 0 SAMUEL LIEBER TREASURER 1.00 X 0 0 0 MARY RUBIN DIRECTOR 1.00 X 0 0 0 TAMAR MALTZ DIRECTOR 1.00 X 0 0 0 MILTON MALTZ DIRECTOR 1.00 X 0 0 0 DANIEL R WEINBERGER CHIEF EXECUTIVE OFFICER & DIRECTOR 40.00 X X 502420 0 16526 THOMAS M HYDE CHIEF OPERATING OFFICER & SECRETARY 40.00 X 316071 0 25862 ANDREW MASLAN SEE SCHED O CHIEF FINANCIAL OFFICER & TREASURER 40.00 X 0 0 0 RON MCKAY DIRECTOR OF BASIC SCIENCES 40.00 X 370352 0 16394 JOEL KLEINMAN ASSOCIATE DIRECTOR OF CLINICAL SCIENCES 40.00 X 370454 0 18079 JIM BARROW ASSOCIATE DIRECTOR OF DRUG DISCOVERY 40.00 X 197907 0 30993 RICHARD STRAUB INVESTIGATOR 40.00 X 157106 0 26657 JOHN MEYERS DIRECTOR OF IT 40.00 X 148932 0 27901 VENKATA MATTAY INVESTIGATOR 40.00 X 249789 0 40199 FENGYU ZHANG INVESTIGATOR 40.00 X 143798 0 19506 JIE ZHANG INVESTIGATOR 40.00 X 156032 0 9357 2612861 0 231474 23 1 1 0 KING AND SPALDING LLP PO BOX 116133 ATLANTA GA 303686133 LEGAL 336800 ARNOLD & PORTER LLP PO BOX 37116 BALTIMORE MD 21297 LEGAL 191452 SCD INFORMATION TECHNOLOGY 6630 ELI WITNEY DRIVE SUITE E COLUMBIA MD 21046 IT 114102 3 182825 258490 441315 CONTRACT REVENUE 900099 5000506 5000506 5000506 1032333 1032333 11140428 9494911 1645517 1645517 1645517 AMORT.CONTRIB.DISC. 900099 915142 915142 915142 9034813 5000506 0 3592992 X 350000 350000 77500 77500 1867189 1080041 787148 6590122 6091707 498415 214007 207332 6675 891683 761005 130678 518398 446674 71724 663861 29109 634752 43640 43640 50000 50000 629404 412071 217333 611093 383166 227927 84704 21131 63573 2227558 2827783 -600225 438075 291572 146503 35111 13210 21901 47216 841 46375 1910257 1067938 842319 39785 39785 GENERAL LAB SUPPLIES 2302946 2294506 8440 OTHER LAB EXPENSE 919119 861573 57546 148796 35172 113624 20660464 17252331 3358133 50000 533046 4752706 12639901 7344709 36915387 24838442 59028 59350 95057 142886 14233246 4777698 10243510 9455548 39608451 44327845 214959 569763 100309339 91491249 1114431 1578475 563407 1564271 2300000 2300000 1663190 1599545 5641028 7042291 X 52307148 54286294 42361163 30162664 94668311 84448958 100309339 91491249 -11625651 1406298 0 X 0 1 X 0 0 X JOHNS HOPKINS UNIVERSITY HOSPITAL BALTIMORE MD RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7430443 1881038 5549405 6060112 2592703 3467409 742691 303957 438734 9455548 DEFERRED RENT 1275814 CAPITAL LEASE 206040 OTHER NONCURRENT LIABILITIES 117691 1599545 X 10441111 1406298 1406298 9034813 0 9034813 20660464 0 20660464 0 20660464 PART X, LINE 2: THE INSTITUTE FOLLOWS THE PROVISIONS OF ASC 740-10 RELATED TO ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. INCOME TAX BENEFITS ARE RECOGNIZED FOR INCOME TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, ONLY WHEN IT IS DETERMINED THAT THE INCOME TAX POSITION WILL MORE-LIKELY-THAN-NOT BE SUSTAINED UPON EXAMINATION BY TAXING AUTHORITIES. THE INSTITUTE ANALYZED TAX POSITIONS TAKEN FOR FILING WITH THE INTERNAL REVENUE SERVICE AND ALL STATE JURISDICTIONS WHERE IT OPERATES. THE INSTITUTE BELIEVES THAT INCOME TAX FILING POSITIONS WILL BE SUSTAINED UPON EXAMINATION AND DOES NOT ANTICIPATE ANY ADJUSTMENTS THAT WOULD RESULT IN A MATERIAL ADVERSE EFFECT ON THE INSTITUTE'S FINANCIAL CONDITION, RESULTS OF OPERATIONS OR CASH FLOWS. ACCORDINGLY, THE INSTITUTE HAS NOT RECORDED ANY RESERVES, OR RELATED ACCRUALS FOR INTEREST AND PENALTIES FOR UNCERTAIN INCOME TAX POSITIONS AT JUNE 30, 2014 AND 2013. THE INSTITUTE IS SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS FROM FISCAL YEAR END 2011 FORWARD; HOWEVER, THERE ARE CURRENTLY NO AUDITS FOR ANY OPEN TAX PERIODS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - 0 0 GRANTS RESEARCH 77500 0 0 0 0 0 0 77500 0 77500 EUROPE (INCLUDING ICELAND & GREENLAND) - RESEARCH 50000 WIRE TRANSFERS EUROPE (INCLUDING ICELAND & GREENLAND) 27500 2 0 0 0 0 0 0 0 PART I, LINE 2: THIS AGREEMENT PROVIDES FOR MONITORING OF GRANT FUNDS. X X 1 COMMUNITY COUNSELING SERVICE PO BOX 824885 PHILADELPHIA PA 19182 PLANNING SESSIONS AND A REVENUE GENERATION STRATEGY REPORT. 0 0 50000 -50000 50000 -50000 1 COLUMBIA UNIVERSITY PO BOX 29789 NEW YORK NY 100879789 135598093 501(C)(3) 350000 COLLABORATION AGREEMENT 1 0 PART I, LINE 2: THE ONLY GRANT MADE WAS TO COLUMBIA UNIVERSITY UNDER A COLLABORATION AGREEMENT. THIS AGREEMENT PROVIDES FOR MONITORING OF GRANT FUNDS. 1 X X 0 0 0 0 0 0 0 0 0 DANIEL R WEINBERGER CHIEF EXECUTIVE OFFICER & DIRECTOR 502420 0 0 0 0 0 15300 0 1226 0 518946 0 0 0 THOMAS M HYDE CHIEF OPERATING OFFICER & SECRETARY 316071 0 0 0 0 0 10050 0 15812 0 341933 0 0 0 RON MCKAY DIRECTOR OF BASIC SCIENCES 370352 0 0 0 0 0 15300 0 1094 0 386746 0 0 0 JOEL KLEINMAN ASSOCIATE DIRECTOR OF CLINICAL SCIEN 320454 0 50000 0 0 0 813 0 17266 0 388533 0 0 0 JIM BARROW ASSOCIATE DIRECTOR OF DRUG DISCOVERY 197907 0 0 0 0 0 12026 0 18967 0 228900 0 0 0 RICHARD STRAUB INVESTIGATOR 157106 0 0 0 0 0 9717 0 16940 0 183763 0 0 0 JOHN MEYERS DIRECTOR OF IT 148932 0 0 0 0 0 9079 0 18822 0 176833 0 0 0 VENKATA MATTAY INVESTIGATOR 244789 0 5000 0 0 0 15128 0 25071 0 289988 0 0 0 FENGYU ZHANG INVESTIGATOR 143798 0 0 0 0 0 6589 0 12917 0 163304 0 0 0 JIE ZHANG INVESTIGATOR 126032 0 30000 0 0 0 2250 0 7107 0 165389 0 0 0 STEVE LIEBER DIRECTOR 17952821 FOUNDING PARTNER OF ALPINE WOODS CAPITAL INVESTORS LLC WHERE THE ORGANIZATION HAS SIGNIFICANT INVESTMENTS 0 SAMUEL LIEBER DIRECTOR AND TREASURER 17952921 CHIEF EXECUTIVE OFFICER OF ALPINE WOODS CAPITAL INVESTORS LLC WHERE THE ORGANIZATION HAS SIGNIFICANT INVESTMENTS 0 FORM 990, PART III, LINE 2 IN FY 2014, THE LIEBER INSTITUTE ENTERED INTO SEVERAL NEW COLLABORATIVE EFFORTS WITH PHARMACEUTICAL COMPANIES: THE TWO LARGEST WERE ASTRAZENECA AND UCB. THESE COLLABORATIVE EFFORTS WERE AIMED AT IDENTIFING AND SCREENING POTENTIAL NEW EFFECTIVE THERAPIES FOR MENTAL DISORDERS. FORM 990, PART VI, SECTION A, LINE 2 STEVE LIEBER, CONSTANCE LIEBER, SAMUEL LIEBER AND MARY RUBIN HAVE A FAMILY RELATIONSHIP. TAMAR AND MILTON MALTZ HAVE A FAMILY RELATIONSHIP. STEVE LIEBER AND SAMUEL LIEBER HAVE A BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTANT AND REVIEWED IN DRAFT FORM BY MANAGEMENT AND THE ORGANIZATION'S ATTORNEY. IT IS CIRCULATED TO THE BOARD OF DIRECTORS VIA EMAIL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THERE ARE TWO CONFLICT OF INTEREST POLICIES. ONE GOVERNS DIRECTORS, OFFICERS AND KEY EMPLOYEES. PURSUANT TO THIS POLICY, THE COVERED PERSONS MUST SUBMIT A CONFLICT OF INTEREST DISCLOSURE FORM WHEN THEY JOIN OR ARE APPOINTED AND ANNUALLY THEREAFTER. THE SECOND POLICY PRIMARILY GOVERNS RESEARCHERS. ALL COVERED EMPLOYEES UNDER THIS POLICY ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST POLICY UPON COMMENCEMENT OF EMPLOYMENT. COVERED PERSONS UNDER EACH POLICY ARE REQUIRED TO DISCLOSE NEW CONFLICTS OF INTEREST TO MANAGMENT AS SOON AS THEY ARISE. FORM 990, PART VI, SECTION B, LINE 15 THE ORGANIZATION IS IN THE PROCESS OF ESTABLISHING A PROCESS FOR REVIEWING COMPENSATON. AN INDEPENDENT FIRM WAS HIRED TO PROVIDE A COMPENSATION STUDY AND AN INITIAL REVIEW OF COMPENSATION AND GUIDANCE WITH RESPECT OT POLICIES AND PROCEDURES TO BE FOLLOWED. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. PART VII, SECTION A, COMPENSATION SCHEDULE ANDREW MASLAN, CHIEF FINANICAL OFFICER, WAS NOT HIRED UNTIL AFTER DECEMBER 31, 2013. SINCE THIS SCHEDULE REPORTS COMPENSATION FOR THE CALENDAR YEAR ENDED WITHIN THE FISCAL YEAR, THERE IS NO COMPENSATION FOR MR. MASLAN REPORTED ON THIS JUNE 30, 2014 FORM 990. HE WILL HAVE COMPENSATION REPORTED ON THE JUNE 30, 2015 FORM 990. FORM 990, PART IX, LINE 16 LINE 16, COLUMN A REPRESENTS RENT, UTILITIES, AND CERTAIN OTHER DIRECT OCCUPANCY COSTS TOTALING APPROXIMATELY $2.2 MILLION. LINE 16, COLUMN B REPRESENTS TOTAL FACILITY COSTS (INCLUDING DIRECT OCCUPANCY COSTS), ALLOCATED FROM MANAGEMENT AND GENERAL TO PROGRAM SERVICES OF APPROXIMATELY $2.8 MILLION. AS A RESULT, THE SCHEDULE REFLECTS A NET NEGATIVE NUMBER IN COLUMN C.